Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
What is Metabolism?00:52

What is Metabolism?

133.7K
Overview
133.7K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

250
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
250
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

1.0K
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
1.0K
Metabolic States of the Body: The Postabsorptive State01:18

Metabolic States of the Body: The Postabsorptive State

1.5K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of Bariatric Surgery and Obesity Medicines on Human Eating Behavior.

Annual review of nutrition·2026
Same author

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation·2026
Same author

Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.

Obesity science & practice·2026
Same author

Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial.

Human reproduction (Oxford, England)·2026
Same author

Combining glucagon-like peptide 1 analogues with sodium-glucose cotransporter 2 inhibitors to treat patients with type 1 diabetes, BMI > 25 kg/m<sup>2</sup>, and chronic kidney disease - A randomised, controlled pilot study.

Diabetes research and clinical practice·2025

Related Experiment Video

Updated: Mar 3, 2026

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.8K

Metabolic Surgery in a Pill.

Alexander D Miras1, Carel W le Roux2

  • 1Investigative Science, Imperial College London, London SW7 2AZ, UK.

Cell Metabolism
|May 4, 2017
PubMed
Summary
This summary is machine-generated.

Bariatric surgery is now viewed as a metabolic treatment, not just for weight loss. Researchers are exploring a metabolic "polypill" to achieve surgical benefits non-surgically.

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

1.1K

Related Experiment Videos

Last Updated: Mar 3, 2026

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.8K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

1.1K

Area of Science:

  • Metabolic surgery
  • Endocrinology
  • Gastroenterology

Background:

  • Bariatric surgery has evolved from a weight-loss intervention to a treatment for metabolic disorders and end-organ damage.
  • Recent research indicates that the mechanisms behind bariatric surgery extend beyond mechanical restriction and calorie malabsorption.
  • The field of metabolic control interventions, including dietary, pharmacological, and medical devices, has seen rapid recent advancements.

Purpose of the Study:

  • To discuss the evolution of bariatric surgery as a metabolic treatment.
  • To explore the potential of a metabolic "polypill" to replicate the clinical efficacy of bariatric surgery.
  • To bridge the gap between surgical interventions and non-surgical metabolic therapies.

Main Methods:

  • Review of mechanistic studies in humans and rodents over the past decade.
  • Analysis of recent advancements in dietary, pharmacological, and medical device interventions for weight loss and metabolic control.
  • Discussion of the concept of a metabolic "polypill".

Main Results:

  • Bariatric surgery's effects are increasingly understood to be mediated by metabolic pathways, not solely mechanical ones.
  • Significant progress has been made in developing non-surgical approaches for metabolic control.
  • The development of a metabolic "polypill" is being considered as a way to achieve surgical-like metabolic benefits.

Conclusions:

  • Bariatric surgery's role in metabolic disease management is well-established and extends beyond its initial mechanical aims.
  • Non-surgical interventions are rapidly advancing, offering new avenues for metabolic control.
  • A metabolic "polypill" represents a promising future direction for harnessing the therapeutic power of bariatric surgery without surgical intervention.